Related references
Note: Only part of the references are listed.Prognostic Factors for Localized Clear Cell Renal Cell Carcinoma and Their Application in Adjuvant Therapy
Kalle E. Mattila et al.
CANCERS (2022)
The Efficacy of Adjuvant Targeted Therapy in Patients with Advanced Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
Wingkeung Yiu et al.
COMPUTATIONAL AND MATHEMATICAL METHODS IN MEDICINE (2022)
Nanomedicine tactics in cancer treatment: Challenge and hope
Mazhar Salim Al-Zoubi et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2022)
A Nanoparticle's Journey to the Tumor: Strategies to Overcome First-Pass Metabolism and Their Limitations
Joshua J. Milligan et al.
CANCERS (2022)
Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline
W. Kimryn Rathmell et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Multi-target tyrosine kinase inhibitor nanoparticle delivery systems for cancer therapy
Wenjing Xu et al.
MATERIALS TODAY BIO (2022)
Approaches to Improve Macromolecule and Nanoparticle Accumulation in the Tumor Microenvironment by the Enhanced Permeability and Retention Effect
Victor Ejigah et al.
POLYMERS (2022)
Poly lactic-co-glycolic acid-based nanoparticles as delivery systems for enhanced cancer immunotherapy
Lei Gao et al.
FRONTIERS IN CHEMISTRY (2022)
Biopolymeric nanoparticles based effective delivery of bioactive compounds toward the sustainable development of anticancerous therapeutics
Neelam Pathak et al.
FRONTIERS IN NUTRITION (2022)
Cabozantinib for the treatment of solid tumors: a systematic review
Pablo Maroto et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2022)
Targeting Myeloid-Derived Suppressor Cells for Premetastatic Niche Disruption After Tumor Resection
Fan Tang et al.
ANNALS OF SURGICAL ONCOLOGY (2021)
Real-world evidence of cabozantinib in patients with metastatic renal cell carcinoma: Results from the CABOREAL Early Access Program
Laurence Albiges et al.
EUROPEAN JOURNAL OF CANCER (2021)
Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial
Robert J. Motzer et al.
EUROPEAN UROLOGY (2021)
Neoadjuvant and adjuvant immunotherapy in renal cell carcinoma
Alberto Martini et al.
WORLD JOURNAL OF UROLOGY (2021)
Postoperative Natural Killer Cell Dysfunction: The Prime Suspect in the Case of Metastasis Following Curative Cancer Surgery
Marisa Market et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
Chun Loo Gan et al.
CANCER MEDICINE (2021)
Neuroimmune Regulation of Surgery-Associated Metastases
Michael R. Shurin et al.
CELLS (2021)
Nanodrug Delivery Systems Modulate Tumor Vessels to Increase the Enhanced Permeability and Retention Effect
Dong Huang et al.
JOURNAL OF PERSONALIZED MEDICINE (2021)
New Insights into Adjuvant Therapy in Renal Cell Carcinoma: Is the Chapter of VEGF Inhibitors Definitely Closed?
Florent Peyraud et al.
EUROPEAN UROLOGY (2021)
PLGA-based drug delivery system for combined therapy of cancer: research progress
Zhang Ruirui et al.
MATERIALS RESEARCH EXPRESS (2021)
Antiangiogenic Therapy in Clear Cell Renal Carcinoma (CCRC): Pharmacological Basis and Clinical Results
Alessandro Comandone et al.
CANCERS (2021)
Updates on Immunotherapy and Immune Landscape in Renal Clear Cell Carcinoma
Myung-Chul Kim et al.
CANCERS (2021)
Immunogenic Cell Death and Immunomodulatory Effects of Cabozantinib
Fabio Scirocchi et al.
FRONTIERS IN ONCOLOGY (2021)
Association of cabozantinib pharmacokinetics, progression and toxicity in metastatic renal cell carcinoma patients: results from a pharmacokinetics/pharmacodynamics study
L. Cerbone et al.
ESMO OPEN (2021)
Development of a highly pulmonary metastatic orthotopic renal cell carcinoma murine model
Jee Soo Park et al.
BIOLOGY OPEN (2021)
Tyrosine Kinase Inhibitor Cabozantinib Inhibits Murine Renal Cancer by Activating Innate and Adaptive Immunity
Hongyan Liu et al.
FRONTIERS IN ONCOLOGY (2021)
Adjuvant therapy in renal cell carcinoma: Current knowledges and future perspectives
Mathieu Larroquette et al.
CANCER TREATMENT REVIEWS (2021)
High-risk Surgically Resected Renal Cell Carcinoma: Is There a Role for Adjuvant VEGF-TKI Inhibitors?
Giuseppe Fallara et al.
CURRENT PROBLEMS IN CANCER (2021)
An up-to-date evaluation of cabozantinib for the treatment of renal cell carcinoma
Andrea Marchetti et al.
EXPERT OPINION ON PHARMACOTHERAPY (2021)
Antitumor effects of the multi-target tyrosine kinase inhibitor cabozantinib: a comprehensive review of the preclinical evidence
Matteo Santoni et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2021)
Nanotechnology of Tyrosine Kinase Inhibitors in Cancer Therapy: A Perspective
Eleonora Russo et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Progresses in polymeric nanoparticles for delivery of tyrosine kinase inhibitors
Behrouz Foroughi-Nia et al.
LIFE SCIENCES (2021)
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma
T. K. Choueiri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Adjuvant therapy with tyrosine kinase inhibitors for localized and locally advanced renal cell carcinoma: an updated systematic review and meta-analysis
Ekaterina Laukhtina et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2021)
Physiologically Based Pharmacokinetic Modelling of Cabozantinib to Simulate Enterohepatic Recirculation, Drug-Drug Interaction with Rifampin and Liver Impairment
Bettina Gerner et al.
PHARMACEUTICS (2021)
The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment
Muyue Yang et al.
BIOACTIVE MATERIALS (2021)
Recent Advances in Tumor Targeting via EPR Effect for Cancer Treatment
Md Abdus Subhan et al.
JOURNAL OF PERSONALIZED MEDICINE (2021)
Blocking IL1 Beta Promotes Tumor Regression and Remodeling of the Myeloid Compartment in a Renal Cell Carcinoma Model: Multidimensional Analyses
David H. Aggen et al.
CLINICAL CANCER RESEARCH (2021)
Adjuvant therapy for high-risk renal cell carcinoma after nephrectomy how many trials are positive? Only one or more than one
A. Ravaud
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2020)
Quality-adjusted survival with first-line cabozantinib or sunitinib for advanced renal cell carcinoma in the CABOSUN randomized clinical trial (Alliance)
Ronald C. Chen et al.
CANCER (2020)
Adjuvant Therapy for Localized High-Risk Renal Cell Carcinoma
Erika Wood et al.
UROLOGIC CLINICS OF NORTH AMERICA (2020)
Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial
Tim Eisen et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Review of Adjuvant Therapies in Renal Cell Carcinoma: Evidence to Date
Eliana M. C. Tacconi et al.
ONCOTARGETS AND THERAPY (2020)
European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update
Borje Ljungberg et al.
EUROPEAN UROLOGY (2019)
Development of sorafenib loaded nanoparticles to improve oral bioavailability using a quality by design approach
Sang Yeob Park et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2019)
PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN
Abdallah Flaifel et al.
CLINICAL CANCER RESEARCH (2019)
Recent Progress in the Development of Poly(lactic-co-glycolic acid)-Based Nanostructures for Cancer Imaging and Therapy
Ki-Taek Kim et al.
PHARMACEUTICS (2019)
Adjuvant Therapy in High-Risk Renal Cell Cancer: A Systematic Review and Meta-analysis
Irbaz B. Riaz et al.
MAYO CLINIC PROCEEDINGS (2019)
Surgical stress and cancer progression: the twisted tango
Zhiwei Chen et al.
MOLECULAR CANCER (2019)
Adjuvant Tyrosine Kinase Inhibitors in Treatment of Renal Cell Carcinoma: A Meta-Analysis of Available Clinical Trials
Francesco Massari et al.
CLINICAL GENITOURINARY CANCER (2019)
Employment of enhanced permeability and retention effect (EPR): Nanoparticle-based precision tools for targeting of therapeutic and diagnostic agent in cancer
Dnyaneshwar Kalyane et al.
MATERIALS SCIENCE AND ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS (2019)
Cabozantinib in Combination with Immunotherapy for Advanced Renal Cell Carcinoma and Urothelial Carcinoma: Rationale and Clinical Evidence
Paulo Bergerot et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Establishment of a bioluminescent Renca cell line for renal carcinoma research
Jie Ding et al.
INTERNATIONAL UROLOGY AND NEPHROLOGY (2018)
Kidney Cancer Research Network of Canada consensus statement on the role of adjuvant therapy after nephrectomy for high-risk, non-metastatic renal cell carcinoma: A comprehensive analysis of the literature and meta-analysis of randomized controlled trials
Pierre I. Karakiewicz et al.
CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL (2018)
Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results
Robert J. Motzer et al.
EUROPEAN UROLOGY (2018)
Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial
David Cella et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Adjuvant therapy for locally advanced renal cell carcinoma: A meta-analysis and systematic review
Yangyang Bai et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2018)
Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial
M. Gross-Goupil et al.
ANNALS OF ONCOLOGY (2018)
PLGA-Based Nanoparticles in Cancer Treatment
Sima Rezvantalab et al.
FRONTIERS IN PHARMACOLOGY (2018)
Adjuvant Antiangiogenic Agents in Post-nephrectomy Renal Cell Carcinoma: A Systematic Review and Meta-analysis
Mohamad B. Sonbol et al.
EUROPEAN UROLOGY ONCOLOGY (2018)
Does the mobilization of circulating tumour cells during cancer therapy cause metastasis?
Olga A. Martin et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial
Toni K. Choueiri et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Mitochondrial ASncmtRNA-1 and ASncmtRNA-2 as potent targets to inhibit tumor growth and metastasis in the RenCa murine renal adenocarcinoma model
Vincenzo Borgna et al.
ONCOTARGET (2017)
Surgery for Cancer: A Trigger for Metastases
Samer Tohme et al.
CANCER RESEARCH (2017)
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial
Naomi B. Haas et al.
LANCET (2016)
Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy
A. Ravaud et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib
Christopher Jedeszko et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Overexpression of microRNA-95-3p suppresses brain metastasis of lung adenocarcinoma through downregulation of cyclin D1
Su Jin Hwang et al.
ONCOTARGET (2015)
Surgery, wound healing, and metastasis: Recent insights and clinical implications
Wim Ceelen et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2014)
Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy
Amanda Tracz et al.
JOVE-JOURNAL OF VISUALIZED EXPERIMENTS (2014)
Late recurrence of renal cell carcinoma >5 years after surgery: clinicopathological characteristics and prognosis
Yong Hyun Park et al.
BJU INTERNATIONAL (2012)
Clinical Characteristics and Outcomes of Patients With Recurrence 5 Years After Nephrectomy for Localized Renal Cell Carcinoma
Ari Adamy et al.
JOURNAL OF UROLOGY (2011)
Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system
JS Lam et al.
JOURNAL OF UROLOGY (2005)
Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: An International Multicenter Study
JJ Patard et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease
NK Janzen et al.
UROLOGIC CLINICS OF NORTH AMERICA (2003)
The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices
RA Jain
BIOMATERIALS (2000)